For many cancer patients, an important concern beyond standard treatments is whether there are additional approaches that can suppress cancer cell growth through different biological pathways. In recent years, high-dose vitamin C (high-dose vitamin C) has frequently appeared in patient communities and scientific literature, sparking widespread discussion.
For many breast cancer patients, fighting cancer is not simply about completing a treatment protocol. It is a long-term battle that consumes both physical strength and emotional resilience. Even after surgery, chemotherapy, radiotherapy, targeted therapy, or hormonal therapy, many patients continue to struggle with fatigue, weakened immunity, recurrent infections, and a noticeable decline in quality of life.
For cancer patients, fighting cancer has never been merely a battle to “eliminate cancer cells completely.” Increasingly, patients come to realize during treatment that what truly influences disease progression is the body’s overall condition—especially whether the immune system can withstand long-term stress.
For many cancer patients, while undergoing surgery, chemotherapy, targeted therapy, or immunotherapy, a persistent question remains: Are there other approaches that can help the body fight cancer, reduce side effects, or even enhance treatment outcomes?
For cancer patients, fighting cancer has never been a one-way path. As treatment experiences accumulate, more patients come to realize that cancer progression is not determined solely by the tumor itself, but is closely linked to the body’s metabolic state, immune response, oxidative stress, and tumor microenvironment.
Triple-negative breast cancer (TNBC) is widely recognized as one of the most aggressive subtypes of breast cancer. Because tumor cells lack estrogen receptors, progesterone receptors, and HER2, many standard targeted therapies are ineffective. As a result, treatment often relies on chemotherapy and selected immunotherapies. Despite aggressive care, some patients experience early relapse, metastasis, or gradual loss of treatment response.
Triple-negative breast cancer (TNBC) is defined by the absence of estrogen receptors, progesterone receptors, and HER2 expression, accounting for approximately 15–20% of all breast cancers. Compared with other subtypes, TNBC often affects younger patients, shows poorer pathological differentiation, and is characterized by aggressive behavior, with higher rates of recurrence, metastasis, and mortality.
Triple-negative breast cancer (TNBC) is often described as one of the most difficult breast cancer subtypes to treat. It lacks estrogen receptors, progesterone receptors, and HER2 expression, leaving patients with fewer targeted treatment options. TNBC is known for its aggressive biological behavior, rapid disease progression, and higher risks of early recurrence and distant metastasis.
Triple-negative breast cancer (TNBC) is one of the most challenging subtypes of breast cancer. Because tumor cells lack estrogen receptors, progesterone receptors, and HER2 expression, many standard targeted therapies are ineffective. As a result, treatment strategies often rely on chemotherapy and selected immunotherapies, yet recurrence, metastasis, and treatment resistance remain common concerns.
In recent years, immunotherapy has become a major focus in cancer treatment. Breakthroughs in cancers like melanoma have raised hopes that immunotherapy could be a game-changer for many patients. However, in breast cancer, immunotherapy is not suitable for everyone—and it is not a “magic treatment” that automatically means fewer side effects.
